Here's Why Tenet Healthcare (THC) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
THC - Tenet Healthcare Corporation
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$259.50
DETAILS
HIGH:
$288.00
LOW:
$210.00
MEDIAN:
$262.50
CONSENSUS:
$259.50
UPSIDE:
49.33%
Stock News
NIO, Intuit, And Reddit Are Among Top 10 Large-Cap Losers Last Week (May 18-May 22): Are The Others In Your Portfolio?
Large-cap laggards last week were pressured by weak guidance, regulatory concerns, rising bond yields and competitive threats, with technology, EV, healthcare and data center-linked stocks leading the declines.
Is Tenet (THC) a Solid Growth Stock? 3 Reasons to Think "Yes"
Tenet (THC) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Tenet Healthcare Corp (THC) Stock Down 5.0% but Still Overvalued -- GF Score: 79/100
On May 21, 2026, Tenet Healthcare Corp (THC) shares fell 5.0% to a current price of $178.00. This decline comes in the context of a 52-week range of $146.60 to
Investors Heavily Search Tenet Healthcare Corporation (THC): Here is What You Need to Know
Tenet (THC) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Here's Why Tenet Healthcare (THC) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is Tenet (THC) a Buy as Wall Street Analysts Look Optimistic?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Wall Street Analysts Think Tenet (THC) Could Surge 26.16%: Read This Before Placing a Bet
The mean of analysts' price targets for Tenet (THC) points to a 26.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Larry Robbins' Strategic Moves: Significant Reduction in Teva Pharmaceutical Industries Ltd
Insights into Glenview Capital Management's First Quarter 2026 Portfolio Adjustments Larry Robbins (Trades, Portfolio) recently submitted the 13F filing for th
Is Tenet Healthcare (THC) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Tenet Healthcare Corporation (THC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Tenet Healthcare Corporation (THC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Why Tenet Healthcare (THC) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
THC Beats Q1 Earnings Estimates on Strong Ambulatory Growth, Ups '26 EPS View
Tenet Healthcare tops Q1 EPS estimates as admissions and ambulatory growth drive gains, but payer mix pressures and rising costs weigh on margins.
Here is What to Know Beyond Why Tenet Healthcare Corporation (THC) is a Trending Stock
Zacks.com users have recently been watching Tenet (THC) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Tenet to Participate in the BofA Securities Health Care Conference
DALLAS--(BUSINESS WIRE)--Tenet Healthcare Corporation (NYSE: THC) is scheduled to present at the BofA Securities Health Care Conference on Wednesday, May 13, 2026.
Tenet (THC) is an Incredible Growth Stock: 3 Reasons Why
Tenet (THC) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Why Tenet Healthcare (THC) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Tenet Healthcare: I Am Caring A Lot More At Current Levels
Tenet Healthcare trades at just 10x adjusted earnings after a 30% pullback from recent highs, making valuation compelling. 2025 adjusted earnings reached $17 per share, exceeding prior guidance, while the 2026 outlook suggests continued earnings stability and robust buybacks. Revenue growth is driven by higher pricing, with flat volumes and margin pressure, yet overall business stability is maintained.
Brokers Suggest Investing in Tenet (THC): Read This Before Placing a Bet
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Tenet Healthcare Blames Admissions Mix For Soft Q1 Sales
Tenet Healthcare Corporation (NYSE:THC) shares are down on Thursday as the company reported mixed first-quarter results.
Price Targets
Tenet Healthcare price target lowered to $210 from $245 at Baird
$210.00
(was $185.35)
Robert W. Baird
Tenet Healthcare price target lowered to $238 from $257 at Barclays
$238.00
(was $185.35)
Andrew Mok
·
Barclays
Tenet Healthcare price target lowered to $260 from $275 at Stephens
$260.00
(was $183.27)
Scott Fidel
·
Stephens
Tenet Healthcare price target lowered to $254 from $260 at Morgan Stanley
$254.00
(was $183.95)
Morgan Stanley
Tenet Healthcare (THC) PT Raised to $283 at Guggenheim
$283.00
(was $234.58)
Jason Cassorla
·
Guggenheim
Tenet Healthcare price target raised to $270 from $240 at Truist
$270.00
(was $232.06)
Truist Financial
Tenet Healthcare price target raised to $265 from $229 at Wells Fargo
$265.00
(was $231.10)
Stephen Baxter
·
Wells Fargo
Tenet Healthcare price target raised to $271 from $257 at Guggenheim
$271.00
(was $232.26)
Guggenheim
Tenet Healthcare price target raised to $257 from $240 at Barclays
$257.00
(was $232.26)
Andrew Mok
·
Barclays
Tenet Healthcare price target raised to $288 from $260 at UBS
$288.00
(was $233.50)
UBS
Tenet Healthcare price target raised to $260 from $247 at Morgan Stanley
$260.00
(was $228.75)
Morgan Stanley
Tenet Healthcare price target raised to $277 from $253 at RBC Capital
$277.00
(was $226.35)
RBC Capital
Tenet Healthcare price target raised to $250 from $225 at KeyBanc
$250.00
(was $226.35)
Matthew Gillmor
·
KeyBanc
Tenet Healthcare price target raised to $253 from $252 at RBC Capital
$253.00
(was $194.98)
Ben Hendrix
·
RBC Capital
Tenet Healthcare price target lowered to $229 from $252 at Wells Fargo
$229.00
(was $208.24)
Wells Fargo
Tenet Healthcare price target raised to $247 from $232 at Morgan Stanley
$247.00
(was $195.02)
Craig Hettenbach
·
Morgan Stanley
Tenet Healthcare price target raised to $257 from $238 at Guggenheim
$257.00
(was $215.13)
Guggenheim
Tenet Healthcare price target raised to $240 from $229 at Barclays
$240.00
(was $186.68)
Andrew Mok
·
Barclays
Tenet Healthcare price target raised to $240 from $225 at Truist
$240.00
(was $200.74)
Truist Financial
Tenet Healthcare price target raised to $252 from $230 at RBC Capital
$252.00
(was $212.48)
RBC Capital